CSPC Gains NMPA Approval for Phase III Trial of Prusogliptin/Metformin FDC
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured approval from the National Medical Products...
Diabetes
Gan & Lee’s GZR102 Receives NMPA Clinical Trial Clearance for Type 2 Diabetes
China’s Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial clearance...
Medtronic Wins FDA Approval for Simplera Sync Sensor in MiniMed 780G System
US-Irish medical technology firm Medtronic plc (NYSE: MDT) has secured marketing approval from the US...
HighTide Therapeutics’ HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical...
Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply
Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed...
Huadong Medicine’s Semaglutide Injection Accepted for Review by China’s NMPA
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...
Guangzhou Doublle Bioproduct Receives IND Approval for E101 in Type 2 Diabetes
Guangzhou Doublle Bioproduct Co., Ltd. has announced receiving Investigational New Drug (IND) clearance from China’s...
United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement...
Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck’s Gardasil...
Roche and Zealand Pharma Collaborate to Develop Petrelintide for Weight Management
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced a strategic exclusive collaboration and licensing...
Tonghua Dongbao’s Tongboli Under GMP Inspection in Egypt
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced that the on-site Good Manufacturing Practice (GMP) inspection...
Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...
Innogen Pharmaceutical Launches Efsubaglutide Alfa for Type 2 Diabetes in China
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, announced the...
Gan & Lee Pharmaceuticals Doses First Patient in GZR4 Phase III Study for Diabetes
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
Sanofi’s Merilog Biosimilar Wins FDA Approval for Diabetes Treatment
The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis’ (EPA: SAN) Merilog, a biosimilar...
Eli Lilly’s Q4 Sales Soar 45% to $13.53B on Strength of GLP-1 Drugs
Eli Lilly & Co. (NYSE: LLY) reported a robust finish to 2024, with Q4 revenues...
Guangzhou Innogen’s Efsubaglutide Alfa Approved by NMPA for Type 2 Diabetes
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, has announced...
Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for...
Jiangsu Lianhuan Completes Enrollment for Phase III Study of LH-1801 in Type 2 Diabetes
China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) has announced the completion of subject enrollment...
Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the commercial launch of its innovative...